

INTERIM FINANCIAL STATEMENTS
FOR THE FIRST 6 MONTHS OF THE FISCAL YEAR ENDING 31
DECEMBER 2021

AGIMEXPHARM
PHARMACEUTICAL JOINT
STOCK COMPANY

CONTENTS

	Page
1. Contents	1
2. Statement of the Board of Management	2 - 4
3. Report on the Review of Interim Financial Information	5
4. Interim Balance Sheet as of 30 June 2021	6 - 9
5. Interim Income Statement for the first 6 months of the fiscal year ending 31 December 2021	10
6. Interim Cash Flow Statement for the first 6 months of the fiscal year ending 31 December 2021	11 - 12
7. Notes to the Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2021	13 - 37
8. Appendices	38 - 39

STATEMENT OF THE BOARD OF MANAGEMENT

The Board of Management of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") presents this statement together with the Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2021.

Business highlights

The Company is a joint stock company operating in accordance with the Business Registration Certificate No. 1600699279, registered for the first time on 03 June 2004 and amended for the 15th time on 30 July 2021, granted by the Department of Planning and Investment of An Giang Province.

Head office

- Address : No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
- Tel. : (0296) 385 6961- 385 6964
- Fax : (0296) 385 7301

Affiliates:

Affiliate	Address
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 49-51-53, Street No. 3A, Binh Tri Dong B Ward, Binh Tan District, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 207 Huynh Tan Phat Street, Hoa Cuong Nam Ward, Hai Chau District, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint Stock Company - Agimexpharm Pharmaceutical Manufacturing Factory	Vu Trong Phung Street, Thanh An Cluster, My Thoi Ward, Long Xuyen City, An Giang Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, Chau Thanh District, An Giang Province
Agimexpharm Pharmaceutical Joint Stock Company – Tay Nguyen Branch	No. 184/84 Giai Phong Street, Tan Loi Ward, Buon Ma Thuot City, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 28, Lane 94, Ngoc Khanh Street, Giang Vo Ward, Ba Dinh District, Hanoi City

Principal business activities of the Company are:

- Manufacturing medicines, pharmaceutical chemicals and pharmaceutical materials;
- Trading optical, medical, dental and hospital equipment;
- Trading medicines, pharmaceutical products;
- Trading nutritious food;
- Producing and trading cosmetics;
- Trading materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production;
- Trading vaccines and medical biological products;
- Manufacturing bottled water (the Company must comply with the Law on food safety and hygiene during operation course);
- Manufacturing functional food;
- Manufacturing, trading and processing cattle feed;
- Manufacturing, trading and processing essential oil from herbs;
- Manufacturing and trading food, nutritious and functional food;
- Printing packages;
- Trading real estates;
- Providing high school education, vocational school, kindergarten, preschool;
- Cooperation in securities trading as transaction agent in accordance with the Law on securities;

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
STATEMENT OF THE BOARD OF MANAGEMENT (cont.)

- Wholesaling machinery, equipment and other spare parts;
- Producing electricity;
- Transmitting and distributing electricity;
- Performing other unclassified professional, scientific and technological activities;
- Installing industrial machinery and equipment;
- Wholesaling food;
- Processing milk and dairy products;
- Distilling, refining and mixing liquor.

Board of Management, Control Board and Board of Directors

The Board of Management, the Control Board and the Board of Directors during the period and as of the date of this statement include:

The Board of Management

Full name	Position	Appointing date
Ms. Pham Thi Bich Thuy	Chairwoman	Appointed on 30 July 2020
Mr. Nguyen Van Kha	Vice Chairman	Appointed on 30 July 2020
Ms. Tran Thi Dao	Member	Appointed on 16 March 2018
Mr. Nguyen Quoc Dinh	Member	Appointed on 16 March 2018
Mr. Pham Uyen Nguyen	Member	Appointed on 16 March 2018

The Control Board

Full name	Position	Appointing date
Ms. Tran Thi Thanh Hang	Chief of the Board	Appointed on 16 March 2018
Ms. Le Thi Thuy Linh	Member	Appointed on 16 March 2018
Ms. Nguyen Hong Ngoc	Member	Appointed on 16 March 2018

The Board of Directors

Full name	Position	Appointing date
Mr. Nguyen Van Kha	General Director	Appointed on 16 March 2018
Ms. Pham Thi Bich Thuy	Deputy General Director	Appointed on 02 January 2018
Mr. Lam Tri Hien	Deputy General Director	Appointed on 22 February 2019
Mr. Vu Minh Tuan	Deputy General Director	Appointed on 01 October 2019
Mr. Huynh Hoang Ha	Deputy General Director	Appointed on 01 January 2021

Legal Representative

The Company's legal representative during the period and as of the date of this statement is Mr. Nguyen Van Kha – General Director (appointed on 16 March 2018).

Auditors

A&C Auditing and Consulting Co., Ltd. has been appointed to review the Company's Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2021.

Responsibilities of the Board of Directors

The Board of Directors of the Company is responsible for the preparation of the Interim Financial Statements to give a true and fair view of the financial position, the financial performance and the cash flows of the Company during the period. In order to prepare these Interim Financial Statements, the Board of Directors must:

- select appropriate accounting policies and apply them consistently;
- make judgments and estimates prudently;

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
STATEMENT OF THE BOARD OF MANAGEMENT (cont.)

- state clearly whether the accounting standards applied to the Company are followed or not, and all the material differences from these standards are disclosed and explained in the Interim Financial Statements;
- prepare the Interim Financial Statements of the Company on the going-concern basis, except for the cases that the going-concern assumption is considered inappropriate;
- design and implement effectively the internal control system in order to ensure that the preparation and presentation of the Interim Financial Statements are free from material misstatements due to frauds or errors.

The Board of Directors hereby ensures that all the accounting books of the Company have been fully recorded and can fairly reflect the financial position of the Company at any time, and that all the accounting books have been prepared in compliance with the applicable Accounting System. The Board of Directors is also responsible for managing the Company's assets and consequently has taken appropriate measures to prevent and detect frauds and other irregularities.

The Board of Directors hereby commits to the compliance with the aforementioned requirements in preparation of the Interim Financial Statements.

Approval of the Financial Statements

The Board of Management hereby approves the accompanying Interim Financial Statements which give a true and fair view of the financial position of the Company as of 30 June 2021, its financial performance and its cash flows for the first 6 months of the fiscal year ending 31 December 2021, in accordance with the Vietnamese Accounting Standards and System as well as other legal regulations related to the preparation and presentation of the Interim Financial Statements.

For and on behalf of the Board of Management,



Phạm Thị Bích Thuy
Chairwoman

Date: 06 August 2021

Head Office	: 02 Trương Sơn St., Tân Bình Dist., Hồ Chí Minh City, Vietnam Tel: +84 (028) 3547 2972 Fax: +84 (028) 3547 2970	kttv@a-c.com.vn
Branch in Hà Nội	: 40 Giang Võ St., Đống Đa Dist., Hà Nội City, Vietnam Tel: +84 (024) 3736 7879 Fax: +84 (024) 3736 7869	kttv.hn@a-c.com.vn
Branch in Nha Trang	: Lot STH 06A.01, Lê Hồng Phong II Urban Area, Phước Hải Ward, Nha Trang City, Vietnam Tel: +84 (0258) 246 5151 Fax: +84 (0258) 246 5806	kttv.nt@a-c.com.vn
Branch in Cần Thơ	: 15-13 Võ Nguyên Giáp St., Cái Rang Dist., Cần Thơ City, Vietnam Tel: +84 (0292) 376 4995 Fax: +84 (0292) 376 4996	kttv.ct@a-c.com.vn

No. 4.0196/21/TC-AC

REPORT ON THE REVIEW OF INTERIM FINANCIAL INFORMATION

To: THE SHAREHOLDERS, THE BOARD OF MANAGEMENT AND THE BOARD OF DIRECTORS **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

We have reviewed the accompanying Interim Financial Statements of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company"), which were prepared on 05 August 2021 (from page 06 to page 39), including the Interim Balance Sheet as of 30 June 2021, the Interim Income Statement, the Interim Cash Flow Statement for the first 6 months of the fiscal year ending 31 December 2021 and the Notes to the Interim Financial Statements.

Responsibility of the Board of Directors

The Board of Directors of the Company is responsible for the preparation, true and fair presentation of these Interim Financial Statements in accordance with the Vietnamese Accounting Standards and System as well as the legal regulations related to the preparation and presentation of the Interim Financial Statements; and responsible for such internal control as the Company's Board of Directors determines necessary to enable the preparation and presentation of the Interim Financial Statements to be free from material misstatement due to frauds or errors.

Responsibility of Auditors

Our responsibility is to express conclusion on these Interim Financial Statements based on our review. We have conducted the review in accordance with the Vietnamese Standard on Review Engagements No. 2410 – Review on interim financial information performed by independent auditor of the entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion of Auditors

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Statements have not given a true and fair view, in all material respects, of the financial position as of 30 June 2021 of the Company, its financial performance and its cash flows for the first 6 months of the fiscal year ending 31 December 2021, in conformity with the Vietnamese Accounting Standards and System as well as other legal regulations related to the preparation and presentation of the Interim Financial Statements.

For and on behalf of

A&C Auditing and Consulting Co., Ltd.

Can Tho Branch



Nguyễn Quốc Ngu – Deputy Director

Audit Practice Registration Certificate No. 3089-2020-008-1

Can Tho City, 06 August 2021

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

INTERIM BALANCE SHEET

(Full form)

As of 30 June 2021

Unit: VND

ITEMS	Code	Note	Ending balance	Beginning balance
A - CURRENT ASSETS	100		445.031.584.455	420.462.797.078
I. Cash and cash equivalents	110	V.1	14.991.443.759	14.868.539.506
1. Cash	111		14.991.443.759	14.868.539.506
2. Cash equivalents	112		-	-
II. Short-term financial investments	120		-	3.018.988.613
1. Trading securities	121		-	-
2. Provisions for devaluation of trading securities	122		-	-
3. Held-to-maturity investments	123	V.2a	-	3.018.988.613
III. Short-term receivables	130		205.498.287.992	197.475.036.542
1. Short-term trade receivables	131	V.3	151.624.011.810	146.917.556.077
2. Short-term prepayments to suppliers	132	V.4	13.444.761.215	7.425.771.311
3. Short-term inter-company receivables	133		-	-
4. Receivable according to the progress of construction contract	134		-	-
5. Receivables for short-term loans	135		-	-
6. Other short-term receivables	136	V.5a	42.407.265.701	45.109.459.888
7. Allowance for short-term doubtful debts	137	V.6	(1.977.750.734)	(1.977.750.734)
8. Deficit assets for treatment	139		-	-
IV. Inventories	140		214.057.931.203	196.323.395.289
1. Inventories	141	V.7	214.057.931.203	196.323.395.289
2. Allowance for inventories	149		-	-
V. Other current assets	150		10.483.921.501	8.776.837.128
1. Short-term prepaid expenses	151	V.8a	1.839.843.862	787.055.750
2. Deductible VAT	152		8.644.077.639	7.989.781.378
3. Taxes and other receivables from the State	153		-	-
4. Trading Government bonds	154		-	-
5. Other current assets	155		-	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
B- NON-CURRENT ASSETS	200		174.892.121.297	178.748.332.725
I. Long-term receivables	210		10.932.005.315	11.743.184.404
1. Long-term trade receivables	211		-	-
2. Long-term prepayments to suppliers	212		-	-
3. Working capital in affiliates	213		-	-
4. Long-term inter-company receivables	214		-	-
5. Receivables for long-term loans	215		-	-
6. Other long-term receivables	216	V.5b	10.932.005.315	11.743.184.404
7. Allowance for long-term doubtful debts	219		-	-
II. Fixed assets	220		129.174.791.445	136.743.073.458
1. Tangible fixed assets	221	V.9	88.058.399.408	95.671.631.001
- Historical cost	222		159.298.953.259	159.954.092.402
- Accumulated depreciation	223		(71.240.553.851)	(64.282.461.401)
2. Financial leased assets	224	V.10	18.946.932.077	18.764.023.363
- Historical cost	225		23.856.016.909	21.658.794.909
- Accumulated depreciation	226		(4.909.084.832)	(2.894.771.546)
3. Intangible fixed assets	227	V.11	22.169.459.960	22.307.419.094
- Initial cost	228		23.918.228.698	23.918.228.698
- Accumulated amortization	229		(1.748.768.738)	(1.610.809.604)
III. Investment property	230		-	-
- Historical costs	231		-	-
- Accumulated depreciation	232		-	-
IV. Long-term assets in process	240		16.711.012.917	8.572.180.271
1. Long-term work in process	241		-	-
2. Construction-in-progress	242	V.12	16.711.012.917	8.572.180.271
V. Long-term financial investments	250		10.309.850.000	10.309.850.000
1. Investments in subsidiaries	251		-	-
2. Investments in joint ventures and associates	252	V.2b	4.643.000.000	4.643.000.000
3. Investments in other entities	253	V.2b	666.850.000	666.850.000
4. Provisions for devaluation of long-term financial investments	254		-	-
5. Held-to-maturity investments	255	V.2a	5.000.000.000	5.000.000.000
VI. Other non-current assets	260		7.764.461.620	11.380.044.592
1. Long-term prepaid expenses	261	V.8b	7.764.461.620	11.380.044.592
2. Deferred income tax assets	262		-	-
3. Long-term components and spare parts	263		-	-
4. Other non-current assets	268		-	-
TOTAL ASSETS	270		619.923.705.752	599.211.129.803

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
C - LIABILITIES	300		405.530.127.418	381.442.215.583
I. Current liabilities	310		379.601.916.531	363.737.578.079
1. Short-term trade payables	311	V.13	80.966.447.057	61.076.172.919
2. Short-term advances from customers	312	V.14	1.847.523.488	1.291.405.198
3. Taxes and other obligations to the State Budget	313	V.15	4.041.127.019	8.115.576.274
4. Payables to employees	314		-	286.705.448
5. Short-term accrued expenses	315	V.16	4.260.714.829	863.277.283
6. Short-term inter-company payables	316		-	-
7. Payable according to the progress of construction contracts	317		-	-
8. Short-term unearned revenue	318	V.17	120.901.198	153.611.596
9. Other short-term payables	319	V.18	14.185.659.531	2.260.948.629
10. Short-term borrowings and financial leases	320	V.19a	253.959.832.948	274.239.493.272
11. Provisions for short-term payables	321		-	-
12. Bonus and welfare funds	322	V.20	20.219.710.461	15.450.387.460
13. Price stabilization fund	323		-	-
14. Trading Government bonds	324		-	-
II. Non-current liabilities	330		25.928.210.887	17.704.637.504
1. Long-term trade payables	331		-	-
2. Long-term advances from customers	332		-	-
3. Long-term accrued expenses	333		-	-
4. Inter-company payables for working capital	334		-	-
5. Long-term inter-company payables	335		-	-
6. Long-term unearned revenue	336		-	-
7. Other long-term payables	337		-	-
8. Long-term borrowings and financial leases	338	V.19b	25.928.210.887	17.704.637.504
9. Convertible bonds	339		-	-
10. Preferred shares	340		-	-
11. Deferred income tax liability	341		-	-
12. Provisions for long-term payables	342		-	-
13. Science and technology development fund	343		-	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province


INTERIM FINANCIAL STATEMENTS


For the first 6 months of the fiscal year ending 31 December 2021


Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
D - OWNER'S EQUITY	400		214.393.578.334	217.768.914.220
I. Owner's equity	410		214.393.578.334	217.768.914.220
1. Capital	411	V.21a	128.351.770.000	128.351.770.000
- Ordinary shares carrying voting rights	411a		128.351.770.000	128.351.770.000
- Preferred shares	411b		-	-
2. Share premiums	412	V.21a	15.458.574.700	15.458.574.700
3. Bond conversion options	413		-	-
4. Other sources of capital	414		-	-
5. Treasury stocks	415		-	-
6. Differences on asset revaluation	416		-	-
7. Foreign exchange differences	417		-	-
8. Investment and development fund	418	V.21a	55.192.833.586	45.088.206.545
9. Business arrangement supporting fund	419		-	-
10. Other funds	420		-	-
11. Retained earnings	421	V.21a	15.390.400.048	28.870.362.975
- Retained earnings accumulated to the end of the previous period	421a		-	28.870.362.975
- Retained earnings of the current period	421b		15.390.400.048	-
12. Construction investment fund	422		-	-
II. Other sources and funds	430		-	-
1. Sources of expenditure	431		-	-
2. Fund to form fixed assets	432		-	-
TOTAL LIABILITIES AND OWNER'S EQUITY	440		619.923.705.752	599.211.129.803

An Giang, 05 August 2021


Do Thi Kim Len
Preparer


Tran Nguyen Minh Hien
Chief Accountant


Nguyen Van Kha
General Director



AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

INTERIM INCOME STATEMENT


(Full form)


For the first 6 months of the fiscal year ending 31 December 2021


Unit: VND

ITEMS	Code	Note	Accumulated from the beginning of the year	
			Current year	Previous year
1. Sales	01	VI.1	256.861.917.332	241.232.400.632
2. Sales deductions	02	VI.2	6.135.055.714	6.741.810.737
3. Net sales	10		250.726.861.618	234.490.589.895
4. Cost of sales	11	VI.3	162.483.684.263	159.058.972.847
5. Gross profit	20		88.243.177.355	75.431.617.048
6. Financial income	21	VI.4	248.342.092	207.211.560
7. Financial expenses	22	VI.5	10.227.360.712	9.264.098.611
In which: Loan interest expenses	23		8.976.373.031	8.075.363.821
8. Selling expenses	25	VI.6	45.753.334.553	34.607.943.878
9. General and administration expenses	26	VI.7	13.387.028.967	13.013.087.513
10. Net operating profit	30		19.123.795.215	18.753.698.606
11. Other income	31	VI.8	214.319.080	127.582.314
12. Other expenses	32		-	-
13. Other profit	40		214.319.080	127.582.314
14. Total accounting profit before tax	50		19.338.114.295	18.881.280.920
15. Current income tax	51	V.15	3.947.714.247	3.760.034.515
16. Deferred income tax	52		-	-
17. Profit after tax	60		15.390.400.048	15.121.246.405
18. Basic earnings per share	70	VI.9a	953	933
19. Diluted earnings per share	71	VI.9a	953	933

An Giang, 05 August 2021


Do Thi Kim Len
Preparer


Tran Nguyen Minh Hien
Chief Accountant


Nguyen Van Kha
General Director



AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

INTERIM CASH FLOW STATEMENT

(Full form)

(Indirect method)

For the first 6 months of the fiscal year ending 31 December 2021

Unit: VND

ITEMS	Code	Note	Accumulated from the beginning of the year	
			Current year	Previous year
I. Cash flows from operating activities				
1. Profit before tax	01		19.338.114.295	18.881.280.920
2. Adjustments				
- Depreciation of fixed assets and investment properties	02	V.9, V.10, V.11	9.147.141.943	7.495.587.125
- Provisions and allowances	03		-	-
- Exchange gain/(loss) due to revaluation of monetary items in foreign currencies	04	VI.5	2.376.080	-
- Gain/(loss) from investing activities	05	VI.4	(192.304.822)	(165.576.301)
- Interest expenses	06	VI.5	8.976.373.031	8.075.363.821
- Others	07		-	-
3. Operating profit before changes of working capital	08		37.271.700.527	34.286.655.565
- Increase/(decrease) of receivables	09		(7.839.114.616)	(4.149.949.037)
- Increase/(decrease) of inventories	10		(17.734.535.914)	(19.527.747.198)
- Increase/(decrease) of payables	11		23.171.798.144	8.050.745.211
- Increase/(decrease) of prepaid expenses	12		2.588.795.787	(1.930.850)
- Increase/(decrease) of trading securities	13		-	-
- Interests paid	14		(8.998.513.461)	(8.346.619.566)
- Corporate income tax paid	15	V.15	(7.388.060.486)	(5.125.835.840)
- Other cash inflows	16		-	-
- Other cash outflows	17	V.20	(1.161.235.933)	(645.884.081)
Net cash flows from operating activities	20		19.910.834.048	4.539.434.204
II. Cash flows from investing activities				
1. Purchases and construction of fixed assets and other non-current assets	21	V.9, V.10, V.12	(11.940.915.503)	(9.097.950.115)
2. Proceeds from disposals of fixed assets and other non-current assets	22		2.197.222.000	1.368.000.000
3. Cash outflow for lending, buying debt instruments of other entities	23		(165.004.453)	-
4. Cash recovered from lending, selling debt instruments of other entities	24		3.183.993.066	2.843.012.870
5. Investments in other entities	25		-	-
6. Withdrawals of investments in other entities	26		-	-
7. Interest earned, dividends and profits received	27	VI.4, V.5a	165.050.816	299.998.899
Net cash flows from investing activities	30		(6.559.654.074)	(4.586.938.346)

This statement should be read in conjunction with the Notes to the Interim Financial Statements

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

Interim Cash Flow Statement (cont.)

ITEMS	Code	Note	Accumulated from the beginning of the year	
			Current year	Previous year
III. Cash flows from financing activities				
1. Proceeds from issuing stocks and capital contributions from owners	31		-	-
2. Repayment for capital contributions and re-purchases of stocks already issued	32		-	-
3. Proceeds from borrowings	33	V.19a,b	249.610.986.996	217.864.264.889
4. Repayment for loan principal	34	V.19a	(257.899.052.060)	(217.695.974.221)
5. Payments for financial leased assets	35	V.19a,b	(3.768.021.877)	(1.793.470.068)
6. Dividends and profit paid to the owners	36	V.21d	(1.172.014.700)	(17.513.280)
<i>Net cash flows from financing activities</i>	<i>40</i>		<u><i>(13.228.101.641)</i></u>	<u><i>(1.642.692.680)</i></u>
Net cash flows during the period	50		123.078.333	(1.690.196.822)
Beginning cash and cash equivalents	60	V.1	14.868.539.506	20.394.813.787
Effects of fluctuations in foreign exchange rates	61		(174.080)	-
Ending cash and cash equivalents	70	V.1	<u>14.991.443.759</u>	<u>18.704.616.965</u>



Do Thi Kim Len
Preparer



Tran Nguyen Minh Hien
Chief Accountant



An Giang, 05 August 2021

Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

I. GENERAL INFORMATION

1. Ownership form

Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") is a joint stock company.

2. Operating field

The Company's operating fields are industrial production and trading.

3. Principal business activities

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines, pharmaceutical products; trade nutritious food; produce and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture functional food; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious and functional food; wholesaling machinery, equipment and other spare parts; producing electricity; transmitting and distributing electricity; performing other unclassified professional, scientific and technological activities; installing industrial machinery and equipment; wholesaling food; processing milk and dairy products; distilling, refining and mixing liquor.

4. Normal operating cycle

Normal operating cycle of the Company is within 12 months.

5. Structure of the Company

Joint ventures

The Company only invests in USA-AGP Phamra, LLC headquartered at No. 14314 Brookhurst Street, Graden Grove City, California, 92843. Principal business activities of this joint venture are to package and trade capsules and bottled tablets of functional food, pharmaceutical materials, ganoderma, cordyceps. As of the balance sheet date, the Company's capital contribution rate at this joint venture is 33,33%, equivalent to the voting rate and ownership rate.

6. Statement of information comparability on the Interim Financial Statements

The figures in the current period can be comparable with corresponding figures in the previous period.

7. Headcount

As of the balance sheet date, the Company's headcount is 364 (headcount at the beginning of the year: 368).

II. FISCAL YEAR AND ACCOUNTING CURRENCY

1. Fiscal year

The fiscal year of the Company is from 01 January to 31 December annually.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

2. Accounting currency unit

The accounting currency unit is Vietnamese Dong (VND) because the Company's transactions are primarily made in VND.

III. ACCOUNTING STANDARDS AND SYSTEM

1. Accounting System

The Company applies the Vietnamese Accounting Standards and System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014 and other Circulars guiding the implementation of Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of Interim Financial Statements.

2. Statement of the compliance with the Accounting Standards and System

The Board of Directors ensures to follow all the requirements of the Vietnamese Accounting Standards and System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014 as well as other Circulars guiding the implementation of Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of Interim Financial Statements.

IV. ACCOUNTING POLICIES

1. Accounting convention

All the Financial Statements are prepared on the accrual basis (except for the information related to cash flows).

2. Foreign currency transactions

Transactions in foreign currencies are converted at the actual exchange rates ruling as of the transaction dates. The ending balances of monetary items in foreign currencies are converted at the actual exchange rates ruling as of the balance sheet date.

Foreign exchange differences arisen from foreign currency transactions during the period shall be included into financial income or financial expenses. Foreign exchange differences due to the revaluation of ending balances of the monetary items in foreign currencies after offsetting their positive differences against negative differences shall be included into financial income or financial expenses.

The exchange rate used to convert foreign currency transactions is the actual exchange rate ruling as at the time of these transactions. The actual exchange rates applied to foreign currency transactions are as follows:

- For the foreign currency trading contract (including spot contract, forward contract, future contract, option contract, currency swap): the exchange rate stipulated in the contracts of trading foreign currency between the Company and the Bank.
- For capital contribution made: the selling rate of the bank where the Company opens its account to receive capital contributed from investors as of the date of capital contribution.
- For receivables: the buying rate ruling as at the time of transaction of the commercial bank where the Company designates the customers to make payments.
- For payables: the selling rate ruling as at the time of transaction of the commercial bank where the Company supposes to make payments.
- For acquisition of assets or immediate payments in foreign currency (not included into payable accounts): the buying rate of the commercial bank where the Company makes payments.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

The exchange rates used to re-evaluate the ending balances of monetary items in foreign currencies are determined according to the following principles:

- For foreign currency deposits: the buying rate of the bank where the Company opens its foreign currency account.
- For monetary items in foreign currencies classified as liabilities: the selling rate of Vietcombank - An Giang Branch where the Company opens its foreign currency account.

3. Cash and cash equivalents

Cash includes cash on hand and demand deposits in banks.

4. Financial investments

Held-to-maturity investments

Investments are classified as held-to-maturity investments that the Company intends and is able to hold to maturity. Held-to-maturity investments include term deposits, bonds for the purpose of receiving periodical interest and other held-to-maturity investments.

Held-to-maturity investments are initially recognized at cost including the purchase cost and other transaction costs. After initial recognition, these investments are recorded at recoverable value. Interest from these held-to-maturity investments after acquisition date is recognized in the profit or loss on the basis of the interest income to be received. Interests arising prior to the Company's acquisition of held-to-maturity investments are recorded as a decrease in the costs as at the acquisition time.

When there are reliable evidences proving that a part or the whole investment cannot be recovered and the loss are reliably determined, the loss is recognized as financial expenses during the period while the investment value is derecognized.

Investments in joint ventures

Joint ventures

A joint venture is an entity which is established by a contractual arrangement whereby the Company and the involved parties undertake an economic activity that is subject to joint control. Joint control is the contractually agreed sharing of control over an economic activity, and exists only when the strategic financial and operating decisions relating to the activity require the unanimous consent of the venturers.

Initially recognition

Investments in joint ventures are initially recognized at costs, including the cost of purchase or capital contributions plus other directly attributable transaction cost. In case of investment in non-monetary assets, the costs of the investment are recognized at the fair value of non-monetary assets at the arising time.

Dividends and profits of the periods prior to the purchase of investments are recorded as a decrease in value of such investments. Dividends and profit of the periods after the purchase of investments are recorded into the Company's revenues.

Provisions for impairment of investments in joint ventures

Provisions for impairment of investments in joint ventures are made when the joint ventures suffer from losses at the rate equal to the difference between the actual capital invested by investors in joint ventures and the actual owner's equity multiplying (x) by the Company's rate of capital contribution over the total actual capital invested by investors in joint ventures. If the joint ventures

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

are consolidated into Consolidated Financial Statements, the basis for impairment provisions is the Consolidated Financial Statements.

Increases/(decreases) in the provisions for impairment of investments in joint ventures as of the balance sheet date are recorded into "Financial expenses".

Investments in equity instruments of other entities

Investments in equity instruments of other entities include such investments in equity instruments that do not enable the Company to have the control, joint control or significant influence on these entities.

Investments in equity instruments of other entities are initially recognized at costs, including cost of purchase plus other directly attributable transaction costs. Values of these investments are derecognized for dividends and profits arising in the periods prior to the acquisition of such investments. Dividends and profit arising in the periods after the acquisition of investments are recorded into the Company's revenue. Particularly, the dividends paid in form of shares are not recorded as an increase in values, but the increasing quantity of shares is followed up.

Provisions for impairment of investments in equity instruments of other entities are made as follows:

- For investments in listed shares or fair value of investments which is reliably measured, provisions are made on the basis of the market value of shares.
- For investments of which the fair value cannot be measured at the time of reporting, provisions are made on the basis of the losses suffered by investees, at the rate equal to the difference between the actual capital invested by investors and the actual owner's equity multiplying (x) by the Company's rate of capital contribution over the total actual capital invested by investors in these investees.

Increases/(decreases) in the provisions for impairment of investments in equity instruments of other entities as of the balance sheet date are recorded into "Financial expenses".

5. Receivables

Receivables are recognized at the carrying amounts less allowances for doubtful debts.

The classification of receivables as trade receivables and other receivables is made according the following principles:

- Trade receivables reflect receivables concerning the commercial nature arising from purchase and sale transactions between the Company and customers who are independent to the Company.
- Other receivables reflect receivables not concerning the commercial nature and irrelevant to purchase and sale transactions.

Allowance is made for each doubtful debt on the basis of estimated loss.

Increases/(decreases) in the obligatory allowance for doubtful debts as of the balance sheet date are recorded into "General and administration expenses".

6. Inventories

Inventories are recognized at the lower of cost or net realizable value.

Cost of inventories is determined as follows:

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

- For materials and merchandises: Costs comprise costs of purchases and other directly relevant costs incurred in bringing the inventories to their present location and conditions.
- Work-in-process: Costs comprise costs of main materials, labor and other directly relevant costs.
- For finished goods: Costs comprise costs of materials, direct labor and directly relevant general manufacturing expenses allocated on the basis of normal operations.

Stock-out costs are determined in accordance with the weighted average method and recorded in line with the perpetual method.

Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Allowance for inventories is recognized for each type of inventories when their costs are higher than their net realizable values. Increases/(decreases) in the obligatory allowance for inventories as of the balance sheet date are recorded into "Costs of sales".

7. Prepaid expenses

Prepaid expenses comprise actual expenses arising and relevant to financial performance in several accounting periods. Prepaid expenses of the Company mainly include:

Expenses of tools

Expenses of tools being put into use are allocated into expenses in accordance with the straight-line method for the maximum period of 03 years.

8. Tangible fixed assets

Tangible fixed assets are determined by their historical costs less accumulated depreciation. Historical costs of tangible fixed assets include all the expenses paid by the Company to bring the asset to its working condition for its intended use. Other expenses arising subsequent to initial recognition are included into historical costs of fixed assets only if it can be clearly demonstrated that the expenditure has resulted in future economic benefits expected to be obtained from the use of these assets. Those which do not meet the above conditions will be recorded into operation costs during the period.

When a tangible fixed asset is sold or disposed, its historical cost and accumulated depreciation are written off, then any gain or loss arising from such disposal is included in the income or the expenses during the period.

Tangible fixed assets are depreciated in accordance with the straight-line method over their estimated useful lives. The depreciation years applied are as follows:

<u>Fixed assets</u>	<u>Years</u>
Buildings and structures	05 – 25
Machinery and equipment	06 – 15
Vehicles	06 – 10
Office equipment	03 – 10

9. Financial leased assets

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incident to ownership belonging to the lessee. Financial leased assets are determined by their historical costs less accumulated depreciation. Historical cost is the lower cost of the fair value of the leased asset at commencement of the lease term and the present value of the minimum lease payments. Discount rate used to calculate the present value of the minimum lease payments is the interest rate

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

implicit in the lease or else mentioned in the lease. If the interest rate implicit in the lease cannot be determined, the incremental borrowing rate at commencement of the lease term will be applied.

Financial leased assets are depreciated in accordance with the straight-line method over their estimated useful lives. If there is no reasonable certainty that the Company will obtain ownership at the end of the lease, the fixed asset shall be depreciated over the shorter of the lease term and the estimated useful life of the asset. The depreciation years of the financial leased assets are as follows:

<u>Fixed assets</u>	<u>Years</u>
Machinery and equipment	03 – 15

10. Intangible fixed assets

Intangible fixed assets are determined by their initial costs less accumulated amortization.

Initial costs of intangible fixed assets include all the costs paid by the Company to bring the asset to its working condition for its intended use. Other costs relevant to intangible fixed assets arising subsequent to initial recognition are included into operation costs during the period only if these costs are associated with a specific intangible fixed asset and result in future economic benefits expected to be obtained from the use of these assets.

When an intangible fixed asset is sold or disposed, its initial costs and accumulated amortization are written off, then any gain or loss arising from such disposal is included in the income or the expenses during the period.

The Company's intangible fixed assets include:

Land use right

Land use right includes all the actual expenses paid by the Company directly related to the land being used such as expenses to obtain the land use right, expenses for house removal, land clearance and ground leveling, registration fees, etc. The land use right is amortized in accordance with the straight-line method over the term specified on the land use right certificate. If the land use right is permanent, it is not amortized.

Computer software

Expenses attributable to computer software, which is not a part associated with the relevant hardware, will be capitalized. Costs of computer software include all the expenses paid by the Company until the date the software is put into use. Computer software is amortized in accordance with the straight-line method in 10 years.

11. Construction-in-progress

Construction-in-progress reflects the expenses (including relevant loan interest expenses following the accounting policies of the Company) directly related to assets under construction and machinery and equipment under installation to serve for production, leasing, and management as well as the repair of fixed assets in progress. These assets are recorded at historical costs and not depreciated.

12. Payables and accrued expenses

Payables and accrued expenses are recorded for the amounts payable in the future associated with the goods and services received. Accrued expenses are recorded based on reasonable estimates for the amounts payable.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

The classification of payables as trade payables, accrued expenses and other payables is made on the basis of following principles:

- Trade payables reflect payables of commercial nature arising from the purchase of goods, services, or assets, of which the seller is an independent entity with the Company.
- Accrued expenses reflect expenses for goods, services received from suppliers or supplied to customers but have not been paid, invoiced or lack of accounting records and supporting documents; pay on leave payable to employees; and accrual of operation expenses.
- Other payables reflect payables of non-commercial nature and irrelevant to purchase, sales of goods or provisions of services.

The payables and accrued expenses are classified as short-term and long-term items in the Interim Balance Sheet on the basis of their remaining term as of the balance sheet date.

13. Owner's equity

Capital

Capital is recorded according to the actual amounts invested by the shareholders.

Share premiums

Share premiums are recorded in accordance with the difference between the issuance price and face value upon the IPO, additional issue or the difference between the re-issuance price and carrying value of treasury shares and the equity component of convertible bonds upon maturity date. Expenses directly related to the additional issue of shares and the re-issuance of treasury shares are recorded as a decrease in share premiums.

14. Profit distribution

Profit after tax is distributed to the shareholders after appropriation for funds under the Charter of the Company as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to the shareholders is made with consideration toward non-cash items in the retained earnings that may affect cash flows and payment of dividends such as profit due to revaluation of assets contributed as investment capital, profit due to revaluation of monetary items, financial instruments and other non-cash items.

Dividends are recorded as payables upon approval of the General Meeting of Shareholders.

15. Recognition of sales and income

Sales of merchandises, finished goods

Sales of merchandises, finished goods shall be recognized when all of the following conditions are satisfied:

- The Company transfers most of risks and benefits incident to the ownership of products or goods to customers.
- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the products, goods sold.
- The amount of sales can be measured reliably. When the contracts stipulate that buyers have the right to return products, goods purchased under specific conditions, sales are recorded only when those specific conditions are no longer exist and buyers retains no right to return products, goods (except for the case that such returns are in exchange for other goods or services).
- The Company received or shall probably receive the economic benefits associated with sale transactions.
- The cost incurred or to be incurred in respect of the sale transaction can be measured reliably.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Interest

Interest is recorded, based on the term and the actual interest rate applied in each particular period.

Dividends and profit shared

Dividends and profit shared are recognized when the Company has the right to receive dividends or profit from the capital contribution. Particularly, the dividends paid in form of shares are not recorded as an increase in value, but the increasing quantity is followed up.

16. Sales deductions

Sales deductions include trade discounts, sales allowances, sales returns incurred in the same period of providing goods, merchandises, in which revenues are derecognized.

In case of goods, merchandises provided in the previous periods but trade discounts, sales allowances, sales returns incurred in the current period, revenues are derecognized as follows:

- If sales allowances, trade discounts, sales returns incur prior to the release of the Interim Financial Statements, revenues are derecognized on the Interim Financial Statements of the current period.
- If sales allowances, trade discounts, sales returns incur after the release of the Interim Financial Statements, revenues are derecognized on the Interim Financial Statements of the following period.

17. Borrowing costs

Borrowing costs are interests and other costs that the Company directly incurs in connection with the borrowing.

Borrowing costs are recorded as an expense when it is incurred. In case the borrowing costs are directly attributable to the construction or the production of an asset in progress, which takes a substantial period of time (over 12 months) to get ready for intended use or sales of the asset, these costs will be included in the cost of that asset. To the extent that the borrowings are especially for the purpose of construction of fixed assets and investment properties, the borrowing cost is eligible for capitalization even if construction period is under 12 months. Incomes arisen from provisional investments as loans are recognized as a decrease in the costs of relevant assets.

In the event that general borrowings are partly used for the acquisition, construction or production of an asset in progress, the costs eligible for capitalization will be determined by applying the capitalization rate to average accumulated expenditure on construction or production of that asset. The capitalization rate is computed at the weighted average interest rate of the borrowings not yet paid during the period, except for particular borrowings serving the purpose of obtaining a specific asset.

18. Expenses

Expenses are those that result in outflows of the Company's economic benefits and are recorded at the time of transactions or when incurrence of the transaction is reliable regardless of whether payment for expenses is made or not.

Expenses and their corresponding revenues are simultaneously recognized in accordance with matching principle. In the event that matching principle conflicts with prudence principle, expenses are recognized based on the nature and regulations of accounting standards in order to guarantee that transactions can be fairly and truly reflected.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**19. Corporate income tax**

Corporate income tax only includes current income tax.

Current income tax

Current income tax is the tax amount computed based on the taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures, non-deductible expenses as well as those of non-taxable income and losses brought forward.

20. Related parties

A party is considered a related party of the Company in case that party is able to control the Company or to cause material effects on the financial decisions as well as the operations of the Company. A party is also considered a related party of the Company in case that party is under the same control or is subject to the same material effects.

Considering the relationship of related parties, the nature of relationship is focused more than its legal form.

21. Segment reporting

A business segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

Segment information is prepared and presented in compliance with the accounting policy in the preparation and presentation of the Interim Financial Statements of the Company.

V. ADDITIONAL INFORMATION ON THE ITEMS OF THE INTERIM BALANCE SHEET**1. Cash and cash equivalents**

	<u>Ending balance</u>	<u>Beginning balance</u>
Cash on hand	10.602.945.537	4.673.412.495
Demand deposits in banks	4.388.498.222	10.195.127.011
Total	14.991.443.759	14.868.539.506

2. Financial investments

The financial investments of the Company include held-to-maturity investments and investments in other entities. The Company's financial investments are as follows:

2a. Held-to-maturity investments

	<u>Ending balance</u>		<u>Beginning balance</u>	
	<u>Original costs</u>	<u>Carrying value</u>	<u>Original costs</u>	<u>Carrying value</u>
Short-term	-	-	3.018.988.613	3.018.988.613
Term deposits	-	-	3.018.988.613	3.018.988.613
Long-term	5.000.000.000	5.000.000.000	5.000.000.000	5.000.000.000
Bonds ⁽ⁱ⁾	5.000.000.000	5.000.000.000	5.000.000.000	5.000.000.000
Total	5.000.000.000	5.000.000.000	8.018.988.613	8.018.988.613

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

(i) These bonds have been mortgaged to secure the loans from VietinBank - An Giang Branch.

2b. Investments in other entities

	Ending balance		Beginning balance	
	Original costs	Provisions	Original costs	Provisions
<i>Investments in joint ventures</i>	4.643.000.000	-	4.643.000.000	-
USA-AGP Pharma, LLC (i)	4.643.000.000	-	4.643.000.000	-
<i>Investments in other entities</i>	666.850.000	-	666.850.000	-
- Imexpharm Corporation (ii)	575.360.000	-	575.360.000	-
- OPC Pharmaceutical Joint Stock Company	36.650.000	-	36.650.000	-
- Mekophar Chemical Pharmaceutical Joint-Stock Company (iii)	54.840.000	-	54.840.000	-
Total	5.309.850.000	-	5.309.850.000	-

(i) According to the Investment Certificate No. 201900695 dated 19 July 2019, granted by the Ministry of Planning and Investment, the Company invests in USA-AGP Pharma, LLC an amount of VND 7.140.000.000 (USD 300.000), equivalent to 50% of charter capital. As of the balance sheet date, the Company invested VND 4.643.000.000 (USD 200.000), equivalent to 33,33% of charter capital. The charter capital to be invested in USA-AGP Pharma, LLC is VND 2.330.000.000 (USD 100.000).

(ii) By purchasing 61.458 shares, the Company holds totally 61.458 shares, equivalent to 0,1% of charter capital of Imexpharm Corporation.

(iii) By purchasing 5.227 shares, the Company holds totally 5.227 shares, equivalent to 0,02% of charter capital of Mekophar Chemical Pharmaceutical Joint-Stock Company.

Fair value

Fair value of investments with listed price is determined at the listed price as of the balance sheet date. The Company has not determined the fair value of the investments without listed price because there is no specific instruction on determination of fair value.

Operation of joint ventures

USA-AGP Pharma, LLC is in the course of workshop construction and has not come into operation yet.

Transactions with joint ventures

The Company has no transaction with its joint venture.

3. Short-term trade receivables

	Ending balance	Beginning balance
<i>Receivables from related parties</i>	58.493.461	2.906.289.227
Imexpharm Corporation	58.493.461	2.906.289.227
<i>Receivables from other customers</i>	151.565.518.349	144.011.266.850
Trans-Asia Hospital Investment Joint-Stock Company	16.347.462.010	16.133.381.116
Other customers	135.218.056.339	127.877.885.734
Total	151.624.011.810	146.917.556.077

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Ending balance of some trade receivables of which the carrying value is VND 64.000.000.000, has been mortgaged to secure the loans from VietinBank – An Giang Branch and Techcombank – An Giang Branch.

4. Short-term prepayments to suppliers

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Prepayments to other suppliers</i>		
Tipharco Pharmaceutical Joint Stock Company	2.020.384.211	-
Khang Gia Design - Construction - Trading Co., Ltd.	1.777.198.000	-
Hung Phat Machinery Equipment Company Limited	1.473.100.000	-
Mr. Nguyen Thanh Vinh	4.000.000.000	4.000.000.000
Ms. Nguyen Thi Kim Chi	1.500.000.000	1.500.000.000
Other suppliers	2.674.079.004	1.925.771.311
Total	13.444.761.215	7.425.771.311

5. Other receivables**5a. Other short-term receivables**

	<u>Ending balance</u>		<u>Beginning balance</u>	
	<u>Value</u>	<u>Allowance</u>	<u>Value</u>	<u>Allowance</u>
<i>Receivables from other organizations and individuals</i>				
Advances	13.808.683.524	-	17.166.074.312	-
Term deposit interests	315.698.630	-	288.444.624	-
Short-term mortgages, deposits	21.610.503.784	-	22.266.219.574	-
Other short-term receivables	6.672.379.763	-	5.388.721.378	-
Total	42.407.265.701	-	45.109.459.888	-

5b. Other long-term receivables

This item reflects long-term mortgages and deposits.

6. Doubtful debts

	<u>Ending balance</u>			<u>Beginning balance</u>		
	<u>Overdue period</u>	<u>Original costs</u>	<u>Recoverable amount</u>	<u>Overdue period</u>	<u>Original costs</u>	<u>Recoverable amount</u>
<i>Other organizations and individuals</i>						
Receivables from other organizations and individuals		1.977.750.734	-		1.977.750.734	-
Trade receivables	Over 03 years	1.977.750.734	-	Over 03 years	1.977.750.734	-
Total		1.977.750.734	-		1.977.750.734	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Fluctuations in allowances for short-term doubtful debts are as follows:

	<u>Current period</u>	<u>Previous period</u>
Beginning balance	1.977.750.734	1.758.362.514
Extraction of allowance	-	-
Ending balance	1.977.750.734	1.758.362.514

7. Inventories

	<u>Ending balance</u>		<u>Beginning balance</u>	
	<u>Original costs</u>	<u>Allowance</u>	<u>Original costs</u>	<u>Allowance</u>
Materials and supplies	99.282.652.764	-	93.666.033.471	-
Work-in-process	17.405.337.930	-	24.033.965.331	-
Finished goods	92.709.738.089	-	75.147.191.071	-
Merchandises	1.337.289.042	-	1.796.115.800	-
Goods on consignment	3.322.913.378	-	1.680.089.616	-
Total	214.057.931.203	-	196.323.395.289	-

Ending balance of some inventories of which the carrying value is VND 150.000.000.000, has been mortgaged to secure the loans from VietinBank – An Giang Branch, Vietcombank – An Giang Branch and Techcombank – An Giang Branch.

8. Prepaid expenses**8a. Short-term prepaid expenses**

	<u>Ending balance</u>	<u>Beginning balance</u>
Expenses of tools	780.012.180	787.055.750
Other short-term prepaid expenses	1.059.831.682	-
Total	1.839.843.862	787.055.750

8b. Long-term prepaid expenses

	<u>Ending balance</u>	<u>Beginning balance</u>
Expenses of tools	4.832.564.692	7.774.554.943
Other long-term prepaid expenses	2.931.896.928	3.605.489.649
Total	7.764.461.620	11.380.044.592

9. Tangible fixed assets

Increases/(decreases) of tangible fixed assets are presented in the attached Appendix 01.

Some tangible fixed assets, of which the net book values are VND 62.443.624.233, have been mortgaged to secure the loans from VietinBank – An Giang Branch and PG Bank – An Giang Branch.

10. Financial leased assets

	<u>Machinery and equipment</u>
Historical costs	
Beginning balance	21.658.794.909
Increase during the period	2.197.222.000
Ending balance	23.856.016.909

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

	Machinery and equipment
Depreciation	
Beginning balance	2.894.771.546
Depreciation during the period	2.014.313.286
Ending balance	4.909.084.832
Net book values	
Beginning balance	18.764.023.363
Ending balance	18.946.932.077

11. Intangible fixed assets

	Land use right	Computer software	Total
Initial costs			
Beginning balance	22.114.149.854	1.804.078.844	23.918.228.698
Ending balance	22.114.149.854	1.804.078.844	23.918.228.698
<i>In which:</i>			
Assets fully amortized but still in use	-	-	-
Amortization			
Beginning balance	371.770.419	1.239.039.185	1.610.809.604
Amortization during the period	18.588.522	119.370.612	137.959.134
Ending balance	390.358.941	1.358.409.797	1.748.768.738
Net book values			
Beginning balance	21.742.379.435	565.039.659	22.307.419.094
Ending balance	21.723.790.913	445.669.047	22.169.459.960

All land use rights, of which the net book values are VND 21.723.790.913, have been mortgaged to secure the loans from VietinBank – An Giang Branch, Vietcombank – An Giang Branch and PG Ban - An Giang Branch.

12. Construction-in-progress

	Beginning balance	Increase during the period	Ending balance
Construction-in-progress			
- <i>Injectable drug factory (*)</i>	8.572.180.271	6.686.787.079	15.258.967.350
- <i>My Thoi warehouse expansion</i>	-	1.080.198.461	1.080.198.461
- <i>My Thoi garage expansion</i>	-	371.847.106	371.847.106
Total	8.572.180.271	8.138.832.646	16.711.012.917

(*) The Company has mortgaged the construction in progress of which the carrying value as at the balance sheet date is VND 15.258.967.350 (Beginning balance: VND 8.572.180.271) to secure loans from Vietinbank - An Giang Branch.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**13. Short-term trade payables**

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Payables to related parties</i>	<i>1.485.336.957</i>	<i>6.269.886.601</i>
Imexpharm Corporation	1.485.336.957	6.269.886.601
<i>Payables to other suppliers</i>	<i>79.481.110.100</i>	<i>54.806.286.318</i>
Branch of Glandcore Company Limited	7.319.526.517	10.019.523.700
Hoai Phuong Pharmaceutical Chemical Company Limited	16.784.127.583	7.595.042.902
Constantia Vietnam Manufacturing Limited Liability Company	6.968.127.435	5.449.652.028
Anpharma Pharmaceutical Company Limited	18.041.287.210	8.973.902.280
Other suppliers	30.368.041.355	22.768.165.408
Total	<u>80.966.447.057</u>	<u>61.076.172.919</u>

The Company has no overdue trade payables.

14. Short-term advances from customers

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Advances from other customers</i>		
Nguyen Vy Pharmaceutical Trading Company Limited	325.779.740	-
Ms. Le Bich Ngoc	453.386.871	530.703.355
Ms. Le Thi Hoan My	447.589.818	405.560.737
Ms. Nguyen Thi Ngoc Phung	204.564.590	199.752.549
Other customers	416.202.469	155.388.557
Total	<u>1.847.523.488</u>	<u>1.291.405.198</u>

15. Taxes and other obligations to the State Budget

	<u>Beginning balance</u>	<u>Amount payable during the period</u>	<u>Amount paid during the period</u>	<u>Ending balance</u>
VAT on imports	121.848.759	1.087.616.764	(1.083.215.525)	126.249.998
Corporate income tax	7.268.230.071	3.947.714.247	(7.388.060.486)	3.827.883.832
Personal income tax	725.497.444	1.081.011.687	(1.719.515.942)	86.993.189
Land rental	-	237.550.800	(237.550.800)	-
Fees, legal fees and other duties	-	12.000.000	(12.000.000)	-
Total	<u>8.115.576.274</u>	<u>6.365.893.498</u>	<u>(10.440.342.753)</u>	<u>4.041.127.019</u>

Value added tax (VAT)

The Company has to pay VAT in accordance with the deduction method. The tax rates applied are as follows:

- Medicines, pharmaceutical products of all kinds 5%
- Cosmetics and functional food of all kinds 10%

Import-export duties

The Company has declared and paid these duties in line with the Customs' notices.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**Corporate income tax**

The Company has to pay corporate income tax at the rate of 20% on taxable income (previous period: 20%).

In 2020, the Company put Binh Hoa Pharmaceutical Factory into operation, which is located in areas with special socio-economic difficulties. Pursuant to the current Law on Corporate Income Tax, the project is entitled to the preferential tax rate of 17% in 10 years for income from business activities in this area; and is exempted from tax in 02 years and reduced 50% of the tax payable in the following 04 years. The year 2021 is the second year that the project is exempted from corporate income tax payable.

Estimated corporate income tax payable during the period is as follows:

	Accumulated from the beginning of the year	
	Current period	Previous period
Total accounting profit before tax	19.338.114.295	18.881.280.920
Increases/(decreases) of accounting profit to determine profit subject to corporate income tax:		
- Increases	1.049.555.389	170.000.000
- Decreases	-	-
Income subject to tax	20.387.669.684	19.051.280.920
Income exempted from tax	-	(7.818.500)
Taxable income	20.387.669.684	19.043.462.420
Corporate income tax rate	20%	20%
Corporate income tax payable at common tax rate	4.077.533.937	3.808.692.484
Differences due to the application of rate other than common tax rate	(19.472.953)	(7.298.695)
Corporate income tax exempted	(110.346.737)	(41.359.274)
Corporate income tax to be paid	3.947.714.247	3.760.034.515

Determination of corporate income tax liability of the Company is based on prevailing regulations on tax. Nonetheless, these tax regulations may change from time to time and tax regulations applicable to variety of transactions can be interpreted differently. Hence, the tax amounts presented in the Interim Financial Statements can be changed upon the inspection of tax authorities.

Other taxes

The Company has declared and paid these taxes in line with the prevailing regulations.

16. Short-term accrued expenses

	Ending balance	Beginning balance
Payables to other organizations		
Loan interest expenses	260.714.829	282.855.259
Expenses on advertising, customer service	4.000.000.000	580.422.024
Total	4.260.714.829	863.277.283

17. Short-term unearned revenues

This item reflects net book values of financial leased assets.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**18. Other short-term payables**

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Payables to related parties</i>	7.869.050.033	1.140.010.000
Imexpharm Corporation – Dividends payable	4.234.819.945	-
Related individuals – Dividends payable	3.634.230.088	1.140.010.000
<i>Payables to other entities and individuals</i>	6.316.609.498	1.120.938.629
Trade Union's expenditure	208.974.678	203.876.616
Receipt of short-term deposits and mortgages	175.800.000	175.800.000
Dividends and profits payable	5.672.452.886	738.330.619
Other short-term payables	259.381.934	2.931.394
Total	14.185.659.531	2.260.948.629

19. Borrowings and financial lease**19a. Short-term borrowings and financial lease**

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Short-term borrowings and financial lease payable to other organizations</i>		
Short-term loans from banks	231.751.839.321	247.556.257.016
- Loan from VietinBank – An Giang Branch ⁽ⁱ⁾	114.672.434.723	124.652.788.389
- Loan from PG Bank – An Giang Branch ⁽ⁱⁱ⁾	74.089.981.695	57.574.182.884
- Loan from Shinhan Bank Vietnam Limited - Song Than Branch	-	16.462.008.324
- Loan from Vietcombank – An Giang Branch ⁽ⁱⁱⁱ⁾	34.791.836.869	38.879.334.416
- Loan from Techcombank – An Giang Branch ^(iv)	8.197.586.034	9.987.943.003
Short-term loans from individuals ^(v)	9.439.999.995	13.639.999.995
Current portions of long-term loans (see Note No. V.19b)	7.058.650.756	7.058.650.756
Current portions of financial lease (see Note No. V.19b)	5.709.342.876	5.984.585.505
Total	253.959.832.948	274.239.493.272

The Company is solvent over short-term loans and financial lease.

- (i) The loan from VietinBank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of credit line is 12 months. This loan is secured by mortgaging bonds, debt claims, inventories, buildings and structures, machinery and equipment, vehicles, office equipment and land use right of the Company (see Notes No. V.2a, V.3, V.7, V.9 and V.11).
- (ii) The loan from PG Bank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of credit line is 12 months. This loan is secured by mortgaging buildings and structures, machinery and equipment, vehicles, office equipment and land use right of the Company (see Notes No. V.9 and V.11).
- (iii) The loan from Vietcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The loan term is within 06 months as in each loan acknowledgement. This loan is secured by mortgaging inventories and land use right of the Company (see Notes No. V.7 and V.11).

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

- (iv) The loan from Techcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The loan term is within 12 months as in each loan acknowledgement. This loan is secured by mortgaging inventories of the Company (see Note No. V.7).
- (v) The unsecured loan from external individuals and the Company's employees is to supplement the working capital for business operation at the interest rate of 7,5%/year.

Details of increases/(decreases) of short-term borrowings and financial lease during the period are as follows:

	Beginning balance	Increase during the period	Transfer from long-term borrowings	Amount paid during the period	Ending balance
Short-term loans from banks	247.556.257.016	229.318.844.891	-	(245.123.262.586)	231.751.839.321
Short-term loans from individuals	13.639.999.995	5.400.000.000	-	(9.600.000.000)	9.439.999.995
Current portions of long-term loans	7.058.650.756	-	3.175.789.474	(3.175.789.474)	7.058.650.756
Current portions of financial lease	5.984.585.505	-	2.758.183.429	(3.033.426.058)	5.709.342.876
Total	274.239.493.272	234.718.844.891	5.933.972.903	(260.932.478.118)	253.959.832.948

19b. Long-term borrowings and financial lease

	Ending balance	Beginning balance
Long-term borrowings and financial lease payable to other organizations		
Long-term loans from banks	16.987.848.297	6.292.928.192
- Loan from VietinBank – An Giang Branch ⁽ⁱ⁾	16.987.848.297	6.292.928.192
Long-term loans from other organizations	3.329.473.682	4.505.263.156
- Loan from An Giang Environment Protection Fund ⁽ⁱⁱ⁾	789.473.682	1.105.263.156
- Loan from Vietnam Environment Protection Fund ⁽ⁱⁱⁱ⁾	2.540.000.000	3.400.000.000
Financial lease	5.610.888.908	6.906.446.156
36-month financial lease from Chailease International Leasing Company Limited for business operation	2.176.336.263	3.963.364.652
36-month financial lease from Finance Leasing Company Limited - Vietnam Joint Stock Commercial Bank for Industry and Trade – Ho Chi Minh Branch for business operation	2.154.986.550	1.119.687.281
36-month financial lease from Vietnam International Leasing Company Limited for business operation	1.279.566.095	1.823.394.223
Total	25.928.210.887	17.704.637.504

The Company is solvent over long-term loans and financial lease.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

- (i) The loan from VietinBank – An Giang Branch is to supplement capital for investment in machinery and equipment for workshop expansion and payment of legal investment costs of the injectable drug factory project at the interest rate applied to each loan acknowledgment. The loan term is 10 years, starting from the first disbursement date. The loan amount is quarterly repaid and the first repayment was made on 25 July 2019. This loan is secured by mortgaging assets, i.e. buildings and structures, machinery and equipment, vehicles, office equipment and all construction works and other assets formed in the future from the injectable drug factory project (see Notes No. V.9 and V.12).
- (ii) The loan from An Giang Environment Protection Fund is to supplement capital for investment in machinery and equipment for workshop expansion at the interest rate of 3,6%/year. The loan term is 05 years, starting from the first disbursement date. The loan amount is quarterly repaid and the first repayment was made on 05 March 2019. This loan is secured by guarantee deed of VietinBank – An Giang Branch.
- (iii) The loan from Vietnam Environment Protection Fund is to supplement capital for investment in machinery and equipment for workshop expansion at the interest rate of 2,6%/year. The loan term is 05 years, starting from the first disbursement date. The loan amount is monthly repaid and the first repayment was made on 04 December 2018. This loan is secured by guarantee deed of VietinBank – An Giang Branch.

Payment schedule of long-term borrowings and financial lease is as follows:

	Total debts	Under 01 year	Over 01 year to 05 years	Over 05 years
Ending balance				
Long-term loans from banks	21.694.920.105	4.707.071.808	16.987.848.297	-
Long-term loans from other organizations	5.681.052.630	2.351.578.948	3.329.473.682	-
Financial lease	11.320.231.784	5.709.342.876	5.610.888.908	-
Total	38.696.204.519	12.767.993.632	25.928.210.887	-
Beginning balance				
Long-term loans from banks	11.000.000.000	4.707.071.808	6.292.928.192	-
Long-term loans from other organizations	6.856.842.104	2.351.578.948	4.505.263.156	-
Financial lease	12.891.031.661	5.984.585.505	6.906.446.156	-
Total	30.747.873.765	13.043.236.261	17.704.637.504	-

Total financial lease payable is as follows:

	Under 01 year	Over 01 year to 05 years	Over 05 years	Total
Ending balance				
Principal	5.709.342.876	5.610.888.908	-	11.320.231.784
Interest	780.703.470	317.177.990	-	1.097.881.460
Financial lease payable	6.490.046.346	5.928.066.898	-	12.418.113.244
Beginning balance				
Principal	5.984.585.505	6.906.446.156	-	12.891.031.661
Interest	863.414.349	547.284.694	-	1.410.699.043
Financial lease payable	6.847.999.854	7.453.730.850	-	14.301.730.704

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Details of increases/(decreases) of long-term borrowings and financial lease are as follows:

	<u>Beginning balance</u>	<u>Increase during the period</u>	<u>Amount paid during the period</u>	<u>Transfer to short-term loans</u>	<u>Ending balance</u>
Long-term loans from banks	6.292.928.192	12.694.920.105	-	(2.000.000.000)	16.987.848.297
Long-term loans from other organizations	4.505.263.156	-	-	(1.175.789.474)	3.329.473.682
Financial lease	6.906.446.156	2.197.222.000	(734.595.819)	(2.758.183.429)	5.610.888.908
Total	17.704.637.504	14.892.142.105	(734.595.819)	(5.933.972.903)	25.928.210.887

The Company has no overdue loans and financial lease.

20. Bonus and welfare funds

	<u>Beginning balance</u>	<u>Increase due to appropriation from profit</u>	<u>Disbursement during the period</u>	<u>Ending balance</u>
Bonus and welfare funds	15.378.947.918	5.321.202.343	(508.935.933)	20.191.214.328
Bonus fund for Executive Officers	71.439.542	609.356.591	(652.300.000)	28.496.133
Total	15.450.387.460	5.930.558.934	(1.161.235.933)	20.219.710.461

21. Owner's equity**21a. Statement of fluctuations in owner's equity**

Information on the fluctuations in owner's equity is presented in the attached Appendix 02.

21b. Details of capital contribution of the owners

	<u>Ending balance</u>	<u>Beginning balance</u>
Imexpharm Corporation	42.348.200.000	42.348.200.000
Mr. Pham Uyen Nguyen	18.751.170.000	18.751.170.000
Mr. Nguyen Van Kha	15.065.100.000	14.400.100.000
Other shareholders	52.187.300.000	52.852.300.000
Total	128.351.770.000	128.351.770.000

21c. Shares

	<u>Ending balance</u>	<u>Beginning balance</u>
Number of shares registered to be issued	12.835.177	12.835.177
Number of shares sold to the public	12.835.177	12.835.177
- Common shares	12.835.177	12.835.177
- Preferred shares	-	-
Number of shares repurchased	-	-
- Common shares	-	-
- Preferred shares	-	-
Number of outstanding shares	12.835.177	12.835.177
- Common shares	12.835.177	12.835.177
- Preferred shares	-	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Face value per outstanding share: VND 10.000.

21d. Profit distribution

During the period, the Company distributed profit of the year 2020 in line with the Resolution No. 01/NQ-AGP.ĐHĐCĐ dated 17 May 2021 of the 2021 Annual General Meeting of Shareholders as follows:

	VND
• Dividends distribution	: 12.835.177.000
• Appropriation for bonus and welfare funds	: 5.321.202.343
• Appropriation for bonus fund for the Board of Management and the Control Board	: 609.356.591
• Appropriation for investment and development fund	: 10.104.627.041

During the period, the Company paid dividends as follows:

	Current period	Previous period
Dividends in the previous year	1.172.014.700	17.513.280
Total	1.172.014.700	17.513.280

22. Off-Interim Balance Sheet items**Foreign currencies**

	Ending balance	Beginning balance
United States Dollar (USD)	4.474,4	4.774,4

VI. ADDITIONAL INFORMATION ON THE ITEMS OF THE INTERIM INCOME STATEMENT**1. Sales****1a. Gross sales**

	Accumulated from the beginning of the year
	Current year Previous year
Sales of merchandises	7.148.112.533 5.688.808.533
Sales of finished goods	249.713.804.799 235.543.592.099
Total	256.861.917.332 241.232.400.632

1b. Sales to related parties

The Company only has sales of goods to Imexpharm Corporation – the major shareholder of the Company as follows:

	Accumulated from the beginning of the year
	Current year Previous year
Sales of merchandises	- 4.870.000
Sales of finished goods	4.846.740.150 7.471.021.850

2. Sales deductions

	Accumulated from the beginning of the year
	Current year Previous year
Trade discounts	4.871.012.739 1.677.294.025

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

		Accumulated from the beginning of the year	
		Current year	Previous year
Sales returns		995.925.399	5.028.559.788
Sales allowances		268.117.576	35.956.924
Total		6.135.055.714	6.741.810.737
3. Costs of sales			
		Accumulated from the beginning of the year	
		Current year	Previous year
Costs of merchandises		6.990.203.618	5.332.384.609
Costs of finished goods sold		155.493.480.645	153.726.588.238
Total		162.483.684.263	159.058.972.847
4. Financial income			
		Accumulated from the beginning of the year	
		Current year	Previous year
Demand deposit interests		7.104.307	7.529.495
Term deposit interests		192.258.459	127.987.065
Dividends and profit shared		46.363	7.818.500
Exchange gain arising		48.932.963	63.876.500
Total		248.342.092	207.211.560
5. Financial expenses			
		Accumulated from the beginning of the year	
		Current year	Previous year
Loan interest expenses		8.976.373.031	8.075.363.821
Exchange loss arising		22.200	37.162.785
Cash discount given to customers		1.248.589.401	1.151.572.005
Exchange loss due to the revaluation of monetary items in foreign currencies		2.376.080	-
Total		10.227.360.712	9.264.098.611
6. Selling expenses			
		Accumulated from the beginning of the year	
		Current year	Previous year
Expenses for employees		11.882.705.019	8.807.979.628
Tools, supplies		97.143.060	11.058.335
Depreciation/(amortization) of fixed assets		62.259.136	16.507.428
External services rendered		32.582.912.990	24.923.506.675
Commission, discount, promotion, advertisement		31.579.347.941	24.062.832.308
Other external services rendered		1.003.565.049	860.674.367
Other expenses		1.128.314.348	848.891.812
Total		45.753.334.553	34.607.943.878

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**7. General and administration expenses**

	Accumulated from the beginning of the year	
	Current year	Previous year
Employees	6.356.649.103	6.109.181.143
Office stationery	1.052.739.712	588.234.936
Depreciation/(amortization) of fixed assets	1.044.855.639	603.895.730
Taxes, fees and legal fees	249.550.800	302.291.800
External services rendered	3.061.077.820	1.049.775.353
Other expenses	1.622.155.893	4.359.708.551
Total	13.387.028.967	13.013.087.513

8. Other income

	Accumulated from the beginning of the year	
	Current year	Previous year
Proceeds from liquidation, disposal of fixed assets	-	29.770.736
Collection of fines for overdue debt	-	66.912.478
Collection of inspection fees	34.418.740	-
Other income	179.900.340	30.899.100
Total	214.319.080	127.582.314

9. Earnings per share**9a. Basic/diluted earnings per share**

	Accumulated from the beginning of the year	
	Current year	Previous year
Accounting profit after corporate income tax	15.390.400.048	15.121.246.405
Appropriation for bonus and welfare funds (*)	(2.836.450.729)	(3.024.249.281)
Appropriation for bonus for the Board of Management and the Control Board (*)	(324.737.441)	(122.482.096)
Profit used to calculate basic/diluted earnings per share	12.229.211.878	11.974.515.028
The average number of ordinary shares outstanding during the period	12.835.177	12.835.177
Basic/diluted earnings per share	953	933

(*) Bonus and welfare funds and bonus for the Board of Management, the Control Board in the current period are temporarily appropriated at the rate as stipulated in the Resolution No. 01/NQ-AGP.ĐHĐCĐ dated 17 May 2021 of the 2021 Annual General Meeting of Shareholders.

The number of ordinary shares used to calculate basic/diluted earnings per share is determined as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
The average number of ordinary shares outstanding during the period	12.835.177	12.835.177
Effects of ordinary shares issued during the period	-	-
Average ordinary shares outstanding during the period	12.835.177	12.835.177

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)**9b. Other information**

There is no transaction over the common share or potential common share from the balance sheet date until the date of these Interim Financial Statements.

10. Operating costs

	Accumulated from the beginning of the year	
	Current year	Previous year
Materials and supplies	137.503.383.592	132.674.164.195
Labor costs	32.048.893.054	28.274.286.798
Depreciation/(amortization) of fixed assets	9.147.141.943	7.495.587.125
External services rendered	40.041.849.609	28.694.235.242
Other expenses	4.463.780.051	9.363.772.512
Total	223.205.048.249	206.502.045.872

VII. OTHER DISCLOSURES**1. Transactions and balances with related parties**

The Company's related parties include the key managers, their related individuals and other related parties.

1a. Transactions and balances with the key managers and their related individuals

The Company's key managers include the Board of Management and the Board of Directors. The key managers' related individuals are their close family members.

Transactions with the key managers and their related individuals

The Company has no sales of goods to the key managers and their related individuals and only has the following transactions with the Board of Management and the Board of Directors:

	Accumulated from the beginning of the year	
	Current year	Previous year
Purchasing shares from other shareholders	665.000.000	-
Dividends distribution	(1.068.009.500)	-

Receivables from and payables to the key managers and their related individuals

Receivables from and payables to the key managers and their related individuals are presented in Note No. V.18.

Income of the Board of Management, the Board of Directors and the Control Board:

	Salary	Bonus	Remuneration	Total income
Current period				
Ms. Pham Thi Bich Thuy – Chairwoman cum Deputy General Director	185.055.735	100.000.000	19.000.000	304.055.735
Mr. Nguyen Van Kha - Vice Chairman cum General Director	484.000.000	270.000.000	30.000.000	784.000.000
Ms. Tran Thi Dao – Member of the Board of Management	-	60.000.000	19.000.000	79.000.000
Mr. Nguyen Quoc Dinh - Member of the Board of Management	-	60.000.000	19.000.000	79.000.000
Mr. Pham Uyen Nguyen - Member of the	-	60.000.000	19.000.000	79.000.000

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

	Salary	Bonus	Remuneration	Total income
Board of Management				
Mr. Lam Tri Hien - Deputy General Director	125.832.910	-	-	125.832.910
Mr. Vu Minh Tuan - Deputy General Director	152.586.540	-	-	152.586.540
Mr. Huynh Hoang Ha - Deputy General Director	153.550.155	-	-	153.550.155
Ms. Tran Thi Thanh Hang - Chief of the Control Board	-	60.000.000	19.000.000	79.000.000
Ms. Le Thi Thuy Linh - Member of the Control Board	81.821.595	17.000.000	9.000.000	107.821.595
Ms. Nguyen Hong Ngoc - Member of the Control Board	-	17.000.000	9.000.000	26.000.000
Total	1.182.846.935	644.000.000	143.000.000	1.969.846.935

Previous period

Mr. Nguyen Van Kha - Chairman cum General Director	544.000.000	30.000.000	60.000.000	634.000.000
Ms. Pham Thi Bich Thuy - Member of the Board of Management cum Deputy General Director	217.384.909	30.000.000	38.000.000	285.384.909
Ms. Tran Thi Dao - Member of the Board of Management	-	30.000.000	38.000.000	68.000.000
Mr. Nguyen Quoc Dinh - Member of the Board of Management	-	30.000.000	38.000.000	68.000.000
Mr. Pham Uyen Nguyen - Member of the Board of Management	-	30.000.000	38.000.000	68.000.000
Mr. Le Van Mac - Deputy General Director	151.384.909	-	-	151.384.909
Mr. Lam Tri Hien - Deputy General Director	124.596.545	-	-	124.596.545
Mr. Vu Minh Tuan - Deputy General Director	154.000.000	-	-	154.000.000
Ms. Tran Thi Thanh Hang - Chief of the Control Board	-	30.000.000	38.000.000	68.000.000
Ms. Le Thi Thuy Linh - Member of the Control Board	-	-	18.000.000	18.000.000
Ms. Nguyen Hong Ngoc - Member of the Control Board	76.991.229	-	18.000.000	94.991.229
Total	1.268.357.592	180.000.000	286.000.000	1.734.357.592

1b. Transactions and balances with other related parties

Other related parties of the Company only include Imexpharm Corporation which is the major shareholder holding 33% of charter capital.

Transactions with other related parties

Apart from sales of goods to other related parties presented in Note No. VI.1b, the Company also purchased merchandises from Imexpharm Corporation for the amount of VND 1.485.336.957 (Previous period: VND 11.064.147.687).

The prices of merchandises supplied to other related parties are market prices. The purchases of merchandises from other related parties are done at the market prices.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2020

Notes to the Interim Financial Statements (cont.)

Receivables from and payables to other related parties

Receivables from and payables to other related parties are presented in Notes No. V.3, V.13 and V.18.

The receivables from other related parties are unsecured and will be paid in cash. There are no allowances for doubtful debts made for the receivables from other related parties.

2. Segment information

Segment information is presented based on business segments and geographical segments. Segment reporting is mainly done on the basis of business segments since the Company's business operations are organized and managed on the basis of the natures of its products.

2a. Information on business segment

Principal business activity of the Company is to trade finished medicines of all kinds. In addition, other business activity of the Company is mainly sale of goods and materials. Sales from other business activity only account for a very small proportion of gross sales (2,78% of gross sales for the first 6 months of 2021). Sales and costs of business activities are presented in Notes No. VI.1a and VI.3.

2b. Information on geographical segment

All business operations of the Company are taken place in Vietnam only.

3. Comparative figures


Changes in accounting policies


During the period, the Company changed the method of preparing the Interim Cash Flow Statement from the direct method to the indirect method. The Board of Directors believes that the indirect method of preparing the Interim Cash Flow Statement will provide useful information about the relationship between the Interim Cash Flow Statement and the Interim Income Statement, the Interim Balance Sheet.


4. Subsequent events

There is no material subsequent event which is required adjustments or disclosures in the Interim Financial Statements.

An Giang, 05 August 2021


Do Thi Kim Len
Preparer


Tran Nguyen Minh Hien
Chief Accountant


Nguyen Van Kha
General Director



AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

Appendix 01: Increases/(decreases) in tangible fixed assets

Unit: VND

	Buildings and structures	Machinery and equipment	Vehicles	Office equipment	Total
Historical costs					
Beginning balance	79.196.018.819	70.401.020.222	9.576.375.207	780.678.154	159.954.092.402
Acquisition during the period	-	1.604.860.857	-	-	1.604.860.857
Liquidation and disposal	-	(2.260.000.000)	-	-	(2.260.000.000)
Ending balance	79.196.018.819	69.745.881.079	9.576.375.207	780.678.154	159.298.953.259
In which:					
Assets fully depreciated but still in use	1.391.877.952	15.490.793.745	1.767.502.843	440.024.517	19.090.199.057
Assets waiting for liquidation	-	-	-	-	-
Depreciation					
Beginning balance	21.378.917.095	36.645.015.985	5.690.455.524	568.072.797	64.282.461.401
Depreciation during the period	2.713.948.796	3.691.616.289	553.138.787	36.165.651	6.994.869.523
Liquidation and disposal	-	(36.777.073)	-	-	(36.777.073)
Ending balance	24.092.865.891	40.299.855.201	6.243.594.311	604.238.448	71.240.553.851
Net book values					
Beginning balance	57.817.101.724	33.756.004.237	3.885.919.683	212.605.357	95.671.631.001
Ending balance	55.103.152.928	29.446.025.878	3.332.780.896	176.439.706	88.058.399.408
In which:					
Assets temporarily not in use	-	-	-	-	-
Assets waiting for liquidation	-	-	-	-	-

Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant



An Giang, 05 August 2021

Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2021

Appendix 02: Statement of fluctuation in owner's equity


Unit: VND

	Capital	Share premiums	Investment and development fund	Retained earnings	Total
Beginning balance of the previous year	128.351.770.000	15.458.574.700	40.473.764.575	28.411.114.408	212.695.223.683
Profit in the previous period	-	-	-	15.121.246.405	15.121.246.405
Appropriation for funds	-	-	9.663.714.526	(15.575.937.408)	(5.912.222.882)
Dividends, profit distribution in the previous period	-	-	-	(12.835.177.000)	(12.835.177.000)
Ending balance of the previous period	128.351.770.000	15.458.574.700	50.137.479.101	15.121.246.405	209.069.070.206
Beginning balance of the current year	128.351.770.000	15.458.574.700	45.088.206.545	28.870.362.975	217.768.914.220
Profit in the current period	-	-	-	15.390.400.048	15.390.400.048
Appropriation for funds	-	-	10.104.627.041	(16.035.185.975)	(5.930.558.934)
Dividends, profit distribution in the current period	-	-	-	(12.835.177.000)	(12.835.177.000)
Ending balance of the current period	128.351.770.000	15.458.574.700	55.192.833.586	15.390.400.048	214.393.578.334


Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

An Giang, 05 August 2021


 Nguyen Van Kha
General Director